Anthrogen CEO Kim Mi-hyung: "Beyond pain relief, we saw potential for cartilage regeneration with an injection"
Predicted impact: Low
CEO interview on cartilage regeneration potential; vague, no financial size or regulatory milestone disclosed.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.